1. Home
  2. NRXP vs SYTA Comparison

NRXP vs SYTA Comparison

Compare NRXP & SYTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRXP
  • SYTA
  • Stock Information
  • Founded
  • NRXP 2015
  • SYTA N/A
  • Country
  • NRXP United States
  • SYTA Canada
  • Employees
  • NRXP N/A
  • SYTA N/A
  • Industry
  • NRXP Biotechnology: Pharmaceutical Preparations
  • SYTA Telecommunications Equipment
  • Sector
  • NRXP Health Care
  • SYTA Telecommunications
  • Exchange
  • NRXP Nasdaq
  • SYTA Nasdaq
  • Market Cap
  • NRXP 32.6M
  • SYTA 38.2M
  • IPO Year
  • NRXP N/A
  • SYTA 2020
  • Fundamental
  • Price
  • NRXP $3.02
  • SYTA $4.18
  • Analyst Decision
  • NRXP Strong Buy
  • SYTA
  • Analyst Count
  • NRXP 4
  • SYTA 0
  • Target Price
  • NRXP $28.50
  • SYTA N/A
  • AVG Volume (30 Days)
  • NRXP 187.5K
  • SYTA 3.6M
  • Earning Date
  • NRXP 08-13-2025
  • SYTA 08-15-2025
  • Dividend Yield
  • NRXP N/A
  • SYTA N/A
  • EPS Growth
  • NRXP N/A
  • SYTA N/A
  • EPS
  • NRXP N/A
  • SYTA N/A
  • Revenue
  • NRXP N/A
  • SYTA $11,740,024.00
  • Revenue This Year
  • NRXP N/A
  • SYTA $18.41
  • Revenue Next Year
  • NRXP N/A
  • SYTA N/A
  • P/E Ratio
  • NRXP N/A
  • SYTA N/A
  • Revenue Growth
  • NRXP N/A
  • SYTA 33.58
  • 52 Week Low
  • NRXP $1.10
  • SYTA $0.93
  • 52 Week High
  • NRXP $6.01
  • SYTA $122.74
  • Technical
  • Relative Strength Index (RSI)
  • NRXP 43.71
  • SYTA 57.59
  • Support Level
  • NRXP $2.89
  • SYTA $4.08
  • Resistance Level
  • NRXP $3.53
  • SYTA $4.56
  • Average True Range (ATR)
  • NRXP 0.15
  • SYTA 0.65
  • MACD
  • NRXP -0.06
  • SYTA 0.04
  • Stochastic Oscillator
  • NRXP 18.97
  • SYTA 54.50

About NRXP NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

About SYTA Siyata Mobile Inc.

Siyata Mobile Inc is engaged in the sale of vehicle mounted, cellular-based communications platforms over advanced 3G (Third generation) mobile networks and cellular booster systems. The company develops, markets and sells a portfolio of rugged handheld Push-to-Talk over Cellular (PoC) smartphone devices. These rugged business-to-business (B2B) environments are focused on enterprise customers, first responders, construction workers, security guards, government agencies, utilities, transportation and waste management, amusement parks, and mobile workers in multiple industries. The company operates in USA, Canada, EMEA and Australia. It derives maximum revenue from USA.

Share on Social Networks: